<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369482</url>
  </required_header>
  <id_info>
    <org_study_id>Clarinex 1560/2014</org_study_id>
    <nct_id>NCT04369482</nct_id>
  </id_info>
  <brief_title>Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL</brief_title>
  <acronym>Clarinex</acronym>
  <official_title>Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the day of surgery, the first eye to be operated is randomised to receive a Vivinex , HOYA
      Surgical Optics GmbH or an Clareon, Alcon, Fort Worth, Texas. The second eye to be operated
      receives the other IOL type.

      A complete biomicroscopic examination, visual acuity testing using autorefractometer,
      contrast sensitivity testing, and standardised retroillumination photography for PCO
      evaluation, will be performed 6 month (30-60 days), 1.5 years (± 3 months) and 3 (± 3 months)
      years postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination, fibrosis, posterior capsule opacification (PCO) score and YAG capsulotomy rate.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCO score</measure>
    <time_frame>3 years</time_frame>
    <description>subjectively and objectively graded: 0-10 (0= no PCO, 10= maximum PCO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>3 years</time_frame>
    <description>UCDVA(uncorrected distance visual acuity), BCDVA (best corrected distance visual acuity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis</measure>
    <time_frame>3 years</time_frame>
    <description>grade of fibrosis assessed subjectively at the slitlamp (grade 0=no fibrosis, grade 3=maximum fibrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective glistening score</measure>
    <time_frame>3 years</time_frame>
    <description>neg, &lt;10, 10-20, 20-30, 30-40, &gt;40 uniform or localized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YAG capsulotomy rate</measure>
    <time_frame>3 years</time_frame>
    <description>described subjectively at the slitlamp: was a YAG capsulotomy performed yes/no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Age Related Cataracts</condition>
  <arm_group>
    <arm_group_label>Alcon Clareon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of an intraocular lens Alcon Clareon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hoya Vivinex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Implantation of an intraocular lens Hoya Vivinex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alcon Clareon</intervention_name>
    <description>Implantation of an intraocular lens Alcon Clareon</description>
    <arm_group_label>Hoya Vivinex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hoya Vivinex</intervention_name>
    <description>Implantation of an intraocular lens Hoya Vivinex</description>
    <arm_group_label>Alcon Clareon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral age-related cataract for which phacoemulsification extraction and posterior
             IOL implantation has planned

          -  Age 50 and older

          -  Visual potential in both eyes of 20/30 or better as determined by investigators
             estimation

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

        Exclusion Criteria:

          -  Preceding intraocular surgery or ocular trauma

          -  Relevant other ophthalmic diseases (such as pseudoexfoliation, glaucoma, uveitis,
             retinal degenerations, etc.)

          -  Laser treatment

          -  Uncontrolled systemic or ocular disease

          -  Infectious disease

          -  Pregnancy/Nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna Allgemeines Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Menapace</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

